PLX4720

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (10)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–10 of 10 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF Fusion1
PLX4720 + Vemurafenib

Clinical trials

Trials with this intervention (0)

Data not yet available

No registered study lists this drug as an intervention yet.

GNAQ Q209P1
PLX4720	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	3	accepted	EID1537 Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequenci… (full text at CIViC) PMID 24504448 · Turajlic et al., 2014 · Open in CIViC	civic

RAC1 P29S1
PLX4720	Cutaneous MelanomaALIAS	Predictive	D	Supports Resistance	4	submitted	EID8056 In vitro and in vivo studies that demonstrate that RAC1-P29S is capable of promoting cell survival and resistance to treatment, specifically BRAF inhibition. The authors expressed both a 4-hydroxytamo… (full text at CIViC) PMID 31257073 · Lionarons et al., 2019 · Open in CIViC	civic

BRAF V600E5
Azacitidine + PI3K/BET Inhibitor LY294002 + Pictilisib + PLX4720Combination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID13227 Proteomic analysis of BRAFV600E in melanoma and CRC cell lines revealed a greater sensitivity to combination therapy approach with either PI3K and methyltransferase inhibitors along with PLX4720 (Vemu… (full text at CIViC) PMID 23251002 · Mao et al., 2013 · Open in CIViC	civic
Pictilisib Bismesylate + PLX4720Combination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID96 Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth a… (full text at CIViC) PMID 23845441 · Rad et al., 2013 · Open in CIViC	civic
PLX4720 + PonatinibCombination	Malignant Thyroid Gland Neoplasm	Predictive	D	Supports Sensitivity Response	4	submitted	EID8033 Ghosh et al. provide compelling evidence that thyroid cancers with a BRAFV600E mutation are sensitive to combined PLX4720 and Ponatinib treatment. They predicted a synergistic effect using HTS of acti… (full text at CIViC) PMID 31937621 · Ghosh et al., 2020 · Open in CIViC	civic
PLX4720 + PonatinibCombination	Malignant Thyroid Gland Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID8040 Both in vitro and in vivo models in Kebebew et al. provide evidence that a combinatorial treatment of PLX4720 (a BRAF inhibitor) and ponatinib (a multi targeting tyrosine kinase inhibitor) shows poten… (full text at CIViC) PMID 31937621 · Ghosh et al., 2020 · Open in CIViC	civic
Nutlin-3 + PLX4720Combination	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID97 Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 melanoma cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly m… (full text at CIViC) PMID 23812671 · Ji et al., 2013 · Open in CIViC	civic

BRAF Overexpression1
Dabrafenib + PLX4720 + Trametinib + VemurafenibCombination	Melanoma	Predictive	D	Supports Resistance	2	submitted	EID10156 Association between BRAF-V600E allele amplification and resistance to MEK and BRAF inhibitors was demonstrated in melanoma cell lines and PDX models. Trametinib resistant cells lines distinctly displa… (full text at CIViC) PMID 24055054 · Villanueva et al., 2013 · Open in CIViC	civic

MITF Overexpression1
PLX4720 + SelumetinibCombination	Melanoma	Predictive	D	Supports Resistance	3	submitted	EID1978 Preliminary analysis of biopsies from BRAF(V600E) melanoma patients revealed that phosphorylated (active) CREB was suppressed by RAF-MEK inhibition but restored in relapsing tumours. Expression of tra… (full text at CIViC) PMID 24185007 · Johannessen et al., 2013 · Open in CIViC	civic